Clinical results of the verapamil in hypertension and atherosclerosis study

Journal of Hypertension

Volumn 15, Issue 11, 1997, Pages 1337-1344

  Rosei, Enrico Agabiti ^a   Dal Palù, Cesare ^b   Leonetti, Gastone ^c   Magnani, Bruno ^d   Pessina, Achille ^b   Zanchetti, Alberto ^c,e  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e Ctro Fisiol Clinica e Ipertensione   (Italy)

Author keywords

Blood pressure; Cardiovascular events; Chlorthalidone; Hyperuricemia; Hypokalemia; Verapamil

Indexed keywords

CAPTOPRIL; CHLORTALIDONE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; POTASSIUM; URATE; VERAPAMIL; CALCIUM CHANNEL BLOCKING AGENT;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ASTHENIA; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; LABORATORY TEST; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SITTING; STATISTICAL ANALYSIS; SUSTAINED RELEASE PREPARATION; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; AGED; ARTERIOSCLEROSIS; BLOOD PRESSURE; DRUG EFFECT; MIDDLE AGED; MULTICENTER STUDY;

ADULT; AGED; ARTERIOSCLEROSIS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CHLORTHALIDONE; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; VERAPAMIL;

EID: 0031278797     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199715110-00019     Document Type: Article

References (25)

1. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al.: Blood pressure, stroke, and coronary heart disease: part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990, 335:765-774
2. Collins R, Peto R, MacMahon S, Herbert P, Friebach NH, Eberlein KA, et al.: Blood pressure, stroke, and coronary heart disease: part 2, short-term reduction in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990, 335:827-839.
3. Zanchetti A: Antihypertensive therapy: pride and prejudice [presidential lecture]. J Hypertens 1995, 13:1522-1528.
4. Lithell H: Insulin resistance and cardiovascular drugs. Clin Exp Hypertens [A] 1992, 14:151-162.
5. Schmeider RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996, 276:1507-1513.
6. Henry PD: Atherosclerosis, calcium and calcium antagonists. Circulation 1985, 55:165B-175B.
7. Zanchetti A: Trials investigating the anti-atherosclerotic effects of antihypertensive drugs. J Hypertens 1996, 14 (suppl 2):S77-S82.
8. Hansson L: The benefits of lowering elevated blood pressure: a critical review of studies of cardiovascular morbidity and mortality in hypertension. J Hypertens 1996, 14:537-544.
9. Zanchetti A, Magnani B, Dal Palù C: Atherosclerosis and calcium-antagonists: the VHAS study. J Hum Hypertens 1992, 6 (suppl 2): 1-8.
10. Magnani B, Dal Palù C, Zanchetti A, on behalf of the VHAS: Preliminary clinical experience with calcium antagonists in atherosclerosis. Drugs 1992, 44 (suppl 1):128-133.
11. Reinfrank K, Eckardt A, Schneider G, Hahn KJ: Long term efficacy and safety of verapamil SR 240 mg in hypertension. Acta Therapeutica 1989, 15:221-234.
12. Mancia G for the Italian Verapamil Study Group: 24 Hour antihypertensive effect of verapamil sustained release 240 mg versus nitrendipine and enalapril in essential hypertension. High Blood Pressure 1993, 2:241-248.
13. Borhani NO, Mercuri M, Buckalew VM, Canossa Terris M, Carr AA, Kappagoda T, et al.: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA 1996, 276:785-791.
14. Borhani NO, Brugger SB, Byington RP for the US MIDAS Research Group: Multicenter study with isradipine and diuretics against atherosclerosis. J Cardiovasc Pharmacol 1990, 16 (suppl 1):S23-S29.
15. The Danish Verapamil Infarction Trial II: Effect of verapamil on mortality and major events after acute myocardial infarction. Am J Cardiol 1990, 66:779-785.
16. Schnaper HW, Applegate WB, Bickalew VM, Canossa-Terris M, Lee M, Borhani NO: MIDAS, adverse events over 3 years of antihypertensive therapy with isradipine vs hydrochlorothiazide [abstract]. Atherosclerosis 1994, 110 (suppl):157.
17. Weidmann P, Gerber A, Mardasini R: Effects of antihypertensive therapy on serum lipids. Hypertension 1983, 5:120-131.
18. Midtbo K, Lauve O, Hals O: No metabolic effects of long term treatment with verapamil in hypertension. Angiology 1988, 39:1025-1029.
19. Lewis GR: Long term results with verapamil in essential hypertension and its influence on serum lipids. Am J Cardiol 1986, 67:35D-38D.
20. Libretti A, Catalano M, on behalf of the SLIP Study Group: Lipid profile during antihypertensive treatment: the SLIP study. Drugs 1993, 46 (suppl 2):16-23.
21. Ad hoc subcommittee of the liaison committee of the World Health Organization and the International Society of Hypertension: Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens 1997, 15:105-115.
22. Psaty BM, Heckberg SR, Kopsell TD, Siscovick D, Raghunathan T, Weiss N, et al.: The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995, 274:620-625.
23. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlick R. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996, 9:695-699.
24. Furberg CD, Psaty BM, Meyer JV: Nifedipine dose-related increase in mortality in patients with heart disease. Circulation 1995, 92:1326-1331.
25. Hansson L, Zanchetti A: The antiatherosclerotic effect of calcium antagonist in man - what did MIDAS actually show? Blood Pressure 1995, 4:133-136.